Study of UBT251 injection for chronic kidney disease
Treatments studied
Part of Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests an investigational injection called UBT251 for people with chronic kidney disease who are overweight. It aims to see if it can reduce protein in the urine and help protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old with a BMI of 24 or higher.
- Your kidney function is moderately reduced (eGFR between 45 and 90).
- You have high levels of protein in your urine (UACR between 300 and 5000).
- You have not used GLP-1 agonists or similar weight-loss drugs in the last 3 months.
- You do not have certain kidney diseases (like lupus nephritis or polycystic kidney disease) or a history of pancreatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called IGT-303 in people with chronic kidney disease caused by type 2 diabetes. It aims to see if the drug is safe and helpful for slowing kidney damage.
This trial tests a new medication called survodutide to see if it can reduce protein in the urine and protect kidney function in people with chronic kidney disease. It may be an option for people who already take standard blood pressure and kidney-protecting pills.
This study tests different doses of an investigational medicine (NNC0519-0130) to see if it can reduce kidney damage in people with chronic kidney disease. It may be an option for you if you have kidney impairment and either have or don't have type 2 diabetes.
This study tests a new medicine called HS-10390 to see if it can help people with chronic kidney disease. It might slow down the disease and protect your kidneys.
This study tests an investigational injection called UBT251 to help people who are overweight or obese lose weight. It may also improve related health issues like high blood pressure or fatty liver. The trial lasts for a period and includes regular check-ins with the study team.
This study looks at how a new injection (HDM1005) is processed by the body in people with different levels of kidney function, including healthy volunteers. It aims to help understand dosing for people with kidney issues.
Hear when a new Obesity &Amp; Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.